As of 2025-07-03, the EV/EBITDA ratio of Cardiff Oncology Inc (CRDF) is -4.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Cardiff's latest enterprise value is 214.75 mil USD. Cardiff's TTM EBITDA according to its financial statements is -51.73 mil USD. Dividing these 2 quantities gives us the above Cardiff EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 13.2x | 12.8x |
| Forward P/E multiples | 17.1x - 32.1x | 20.6x |
| Fair Price | (12.95) - (9.87) | (12.62) |
| Upside | -460.7% - -375.0% | -451.6% |
| Date | EV/EBITDA |
| 2025-06-30 | -3.59 |
| 2025-06-27 | -3.59 |
| 2025-06-26 | -3.60 |
| 2025-06-25 | -3.52 |
| 2025-06-24 | -3.65 |
| 2025-06-23 | -3.60 |
| 2025-06-20 | -3.52 |
| 2025-06-18 | -3.42 |
| 2025-06-17 | -4.29 |
| 2025-06-16 | -4.50 |
| 2025-06-13 | -4.43 |
| 2025-06-12 | -4.41 |
| 2025-06-11 | -4.50 |
| 2025-06-10 | -5.06 |
| 2025-06-09 | -4.50 |
| 2025-06-06 | -4.52 |
| 2025-06-05 | -4.19 |
| 2025-06-04 | -4.19 |
| 2025-06-03 | -4.05 |
| 2025-06-02 | -3.84 |
| 2025-05-30 | -3.92 |
| 2025-05-29 | -3.83 |
| 2025-05-28 | -3.64 |
| 2025-05-27 | -3.52 |
| 2025-05-23 | -3.43 |
| 2025-05-22 | -3.24 |
| 2025-05-21 | -3.26 |
| 2025-05-20 | -3.48 |
| 2025-05-19 | -3.28 |
| 2025-05-16 | -3.15 |
| 2025-05-15 | -3.07 |
| 2025-05-14 | -2.97 |
| 2025-05-13 | -3.03 |
| 2025-05-12 | -3.07 |
| 2025-05-09 | -2.96 |
| 2025-05-08 | -2.92 |
| 2025-05-07 | -2.74 |
| 2025-05-06 | -2.81 |
| 2025-05-05 | -2.98 |
| 2025-05-02 | -3.16 |
| 2025-05-01 | -3.02 |
| 2025-04-30 | -3.06 |
| 2025-04-29 | -3.11 |
| 2025-04-28 | -3.33 |
| 2025-04-25 | -3.24 |
| 2025-04-24 | -3.26 |
| 2025-04-23 | -3.32 |
| 2025-04-22 | -3.46 |
| 2025-04-21 | -3.16 |
| 2025-04-17 | -3.20 |